![Javier Szwarcberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Javier Szwarcberg
Directeur Général chez
SPRUCE BIOSCIENCES, INC.
Fortune : 974 335 $ au 31/05/2026
Profil
Javier Szwarcberg is Chief Executive Officer & Executive Director at Spruce Biosciences, Inc. since 2022.
Formerly, Dr. Szwarcberg was Group VP, Head-Product & Portfolio Development at BioMarin Pharmaceutical, Inc. from 2020 to 2022, Senior VP-Program & Portfolio Management at Ultragenyx Pharmaceutical, Inc. from 2017 to 2020, and Vice President-Clinical & Business Development at Horizon Therapeutics Ltd. (Ireland) from 2016 to 2017.
Education includes a doctorate from Universidad de Buenos Aires and graduate studies at Harvard T.H.
Chan School of Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SPRUCE BIOSCIENCES, INC. 1,78 % | 24/03/2026 | 19 004 ( 1,78 % ) | 974 335 $ | 31/05/2026 |
Postes actifs de Javier Szwarcberg
| Sociétés | Poste | Début |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Directeur Général | 03/01/2022 |
Anciens postes connus de Javier Szwarcberg
| Sociétés | Poste | Fin |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/01/2022 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/02/2020 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Directeur Technique/Scientifique/R&D | 01/10/2017 |
Formation de Javier Szwarcberg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
15
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Horizon Therapeutics Ltd. (Ireland)
 Horizon Therapeutics Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Universidad de Buenos Aires
 Universidad de Buenos Aires Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard T.H. Chan School of Public Health
 Harvard T.H. Chan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company which develops novel therapies for endocrine diseases | Health Technology |
